On December 17, 2024, Roman DBDR Tech Acquisition’s subsidiary, CompoSecure, Inc., finalized the issuance of an earn-out consideration as part of its business combination agreement. The completion marked the issuance of 3.6 million shares of Class A common stock following the achievement of a $15.00 volume-weighted average price per share over a specified period after the merger.
The Business Combination, which took place on December 27, 2021, was executed according to the Agreement and Plan of Merger. This earn-out consideration was triggered by certain stock price thresholds reached on the third anniversary of the merger. Parties involved in the agreement were entitled to additional consideration based on the performance of the stock.
With this issuance, Roman DBDR Tech Acquisition continues to solidify its position post-acquisition, demonstrating a commitment to rewarding stakeholders based on predefined performance metrics. The strategic move aligns with the company’s growth plans and ongoing efforts to enhance shareholder value.
This update signifies a significant milestone for Roman DBDR Tech Acquisition’s subsidiary, reflecting the successful execution of the merger agreement and the ensuing benefits realized by the involved parties.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Roman DBDR Tech Acquisition’s 8K filing here.
About Roman DBDR Tech Acquisition
As of December 27, 2021, Roman DBDR Tech Acquisition Corp. was acquired by CompoSecure, LLC, in a reverse merger transaction. Roman DBDR Tech Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or business combination with one or more businesses in the technology, media, and telecom industries.
See Also
- Five stocks we like better than Roman DBDR Tech Acquisition
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- What does consumer price index measure?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- How to Invest in Small Cap Stocks
- Q4’s Most Upgraded Stocks: Promising Buys for 2025